Femasys Q3 sales rise, driven by FemBloc sales

Reuters11-15

Femasys Q3 sales rise, driven by FemBloc sales

Overview

Femasys Q3 sales increased 31.4% yr/yr, driven by FemBloc sales
Company reduced Q3 net loss compared to prior year
Femasys secured $12 mln financing

Outlook

Company expects cash to fund operations into September 2026
Femasys advancing toward U.S. approval of FemBloc
Company expanding FemBloc commercialization in Europe and Asia-Pacific

Result Drivers

FEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control product
REGULATORY APPROVALS - UK and New Zealand approvals expand FemBloc market reach
COST REDUCTION - Decreased R&D expenses due to commercialization and reduced costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.10

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Femasys Inc is $6.00, about 86.2% above its November 13 closing price of $0.83

Press Release: ID:nGNX1LQMYg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583684851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-15 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583684851","market":"nz","top_or_hot":-1,"title":"Femasys Q3 sales rise, driven by FemBloc sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Femasys Q3 sales rise, driven by FemBloc sales</title></head><body><p><span>Overview</span></p><ul><li><p>Femasys Q3 sales increased 31.4% yr/yr, driven by FemBloc sales</p></li><li><p>Company reduced Q3 net loss compared to prior year</p></li><li><p>Femasys secured $12 mln financing</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash to fund operations into September 2026</p></li><li><p>Femasys advancing toward U.S. approval of FemBloc</p></li><li><p>Company expanding FemBloc commercialization in Europe and Asia-Pacific</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control product</p></li><li><p>REGULATORY APPROVALS - UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> approvals expand FemBloc market reach</p></li><li><p>COST REDUCTION - Decreased R&amp;D expenses due to commercialization and reduced costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.10</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a> is $6.00, about 86.2% above its November 13 closing price of $0.83</p></li></ul><p>Press Release: <span>ID:nGNX1LQMYg</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Femasys Q3 sales rise, driven by FemBloc sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFemasys Q3 sales rise, driven by FemBloc sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-15 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Femasys Q3 sales rise, driven by FemBloc sales</title></head><body><p><span>Overview</span></p><ul><li><p>Femasys Q3 sales increased 31.4% yr/yr, driven by FemBloc sales</p></li><li><p>Company reduced Q3 net loss compared to prior year</p></li><li><p>Femasys secured $12 mln financing</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash to fund operations into September 2026</p></li><li><p>Femasys advancing toward U.S. approval of FemBloc</p></li><li><p>Company expanding FemBloc commercialization in Europe and Asia-Pacific</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control product</p></li><li><p>REGULATORY APPROVALS - UK and <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> approvals expand FemBloc market reach</p></li><li><p>COST REDUCTION - Decreased R&amp;D expenses due to commercialization and reduced costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.10</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/FEMY\">Femasys Inc</a> is $6.00, about 86.2% above its November 13 closing price of $0.83</p></li></ul><p>Press Release: <span>ID:nGNX1LQMYg</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ13I:1","article_id":"2583684851","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583684851","pubTimestamp":1763154606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Femasys Q3 sales rise, driven by FemBloc salesOverviewFemasys Q3 sales increased 31.4% yr/yr, driven by FemBloc salesCompany reduced Q3 net loss compared to prior yearFemasys secured $12 mln financing","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","FEMY":"Femasys Inc","BK4584":"避孕概念","BK4539":"次新股"},"translate_title":"在FemBloc销售的推动下，Femasys第三季度销售额增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FEMY":0.9},"content_text":"Femasys Q3 sales rise, driven by FemBloc salesOverviewFemasys Q3 sales increased 31.4% yr/yr, driven by FemBloc salesCompany reduced Q3 net loss compared to prior yearFemasys secured $12 mln financingOutlookCompany expects cash to fund operations into September 2026Femasys advancing toward U.S. approval of FemBlocCompany expanding FemBloc commercialization in Europe and Asia-PacificResult DriversFEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control productREGULATORY APPROVALS - UK and New Zealand approvals expand FemBloc market reachCOST REDUCTION - Decreased R&D expenses due to commercialization and reduced costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.10Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the medical equipment, supplies & distribution peer group is \"buy\"Wall Street's median 12-month price target for Femasys Inc is $6.00, about 86.2% above its November 13 closing price of $0.83Press Release: ID:nGNX1LQMYgFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583684851","isCrawlerRequest":true}